Buscar
Bright Minds Biosciences Inc
DRUGAñadir a la lista de seguimiento
73.260USD
-1.370-1.84%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
721.85MCap. mercado
PérdidaP/E TTM
Más Datos de Bright Minds Biosciences Inc Compañía
Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.
Información de Bright Minds Biosciences Inc
Símbolo de cotizaciónDRUG
Nombre de la empresaBright Minds Biosciences Inc
Fecha de salida a bolsaFeb 08, 2021
Director ejecutivoMcdonald (Ian B)
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 08
Dirección19 Vestry Street
CiudadNEW YORK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal10013
Teléfono16478658622
Sitio Webhttps://brightmindsbio.com/
Símbolo de cotizaciónDRUG
Fecha de salida a bolsaFeb 08, 2021
Director ejecutivoMcdonald (Ian B)
Ejecutivos de Bright Minds Biosciences Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jeremy Fryzuk
Mr. Jeremy Fryzuk
Independent Director
Independent Director
38.11K
+45.92%
Mr. Nils Christian Bottler
Mr. Nils Christian Bottler
Independent Director
Independent Director
7.50K
+33.33%
Mr. Ian B. Mcdonald
Mr. Ian B. Mcdonald
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Ryan Cheung
Mr. Ryan Cheung
Chief Financial Officer
Chief Financial Officer
--
--
Dr. David M. Weiner
Dr. David M. Weiner
Independent Director
Independent Director
--
--
Dr. Jan Pedersen
Dr. Jan Pedersen
Chief Scientific Officer, Director
Chief Scientific Officer, Director
--
--
Dr. Stephen D. Collins, M.D., Ph.D.
Dr. Stephen D. Collins, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jeremy Fryzuk
Mr. Jeremy Fryzuk
Independent Director
Independent Director
38.11K
+45.92%
Mr. Nils Christian Bottler
Mr. Nils Christian Bottler
Independent Director
Independent Director
7.50K
+33.33%
Mr. Ian B. Mcdonald
Mr. Ian B. Mcdonald
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Ryan Cheung
Mr. Ryan Cheung
Chief Financial Officer
Chief Financial Officer
--
--
Dr. David M. Weiner
Dr. David M. Weiner
Independent Director
Independent Director
--
--
Dr. Jan Pedersen
Dr. Jan Pedersen
Chief Scientific Officer, Director
Chief Scientific Officer, Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Bright Minds Biosciences Inc?
Los cinco principales accionistas de Bright Minds Biosciences Inc son: Mr. Jeremy Fryzuk
¿Cuántas instituciones poseen acciones de Bright Minds Biosciences Inc (DRUG)?
A fecha de 2026Q1, 137 instituciones poseen acciones de Bright Minds Biosciences Inc, con un valor de mercado combinado de aproximadamente 6.71M, lo que representa el 68.61% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -102671.00.